Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management

被引：362

作者：

Lok, Anna S.

Zoulim, Fabien

Locarnini, Stephen

Bartholomeusz, Angeline

Ghany, Marc G.

Pawlotsky, Jean-Michel

Liaw, Yun-Fan

Mizokami, Masashi

Kuiken, Carla

机构：

[1] Univ Michigan, Div Gastroenterol, Ann Arbor, MI 48109 USA

[2] INSERM, U271, F-69008 Lyon, France

[3] Univ Lyon 1, F-69365 Lyon, France

[4] Hospices Civils Lyon, Lyon, France

[5] Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia

[6] NIH, NIDDK, Liver Dis Branch, Bethesda, MD 20892 USA

[7] Univ Paris 12, Hop Henri Mondor, French Natl Reference Ctr Viral Hepatitis B,C & D, Dept Virol, F-94010 Creteil, France

[8] Univ Paris 12, Hop Henri Mondor, INSERM, U841, F-94010 Creteil, France

[9] Chang Gung Univ, Mem Hosp, Liver Res Unit, Taipei, Taiwan

[10] Nagoya City Univ, Grad Sch Med Sci, Dept Clin Mol Informat Med, Nagoya, Aichi, Japan

[11] Los Alamos Natl Lab, Theoret Biol & Biophys Grp, Los Alamos, NM USA

来源：

HEPATOLOGY | 2007年 / 46卷 / 01期

关键词：

D O I：

10.1002/hep.21698

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Substantial advances have been made in the treatment of chronic hepatitis B in the past decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and 4 nucleos(t)ide analogues (NAs). Sustained viral suppression is rarely achieved after withdrawal of a 48-week course of NA therapy, necessitating long, and in many cases, indefinite treatment with increasing risk of development of drug resistance. Antiviral resistance and poor adherence are the most important factors in treatment failure of hepatitis B. Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy.

引用

收藏

页码：254 / 265

页数：12

相关论文

共 84 条

[1] Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B [J].

Ahmed, SNS ;

Tavan, D ;

Pichoud, C ;

Berby, F ;

Stuyver, L ;

Johnson, M ;

Merle, P ;

Abidi, H ;

Trépo, C ;

Zoulim, F .

HEPATOLOGY, 2000, 32 (05) :1078-1088

[2] Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine [J].

Allen, MI ;

Gauthier, J ;

DesLauriers, M ;

Bourne, EJ ;

Carrick, KM ;

Baldanti, F ;

Ross, LL ;

Lutz, MW ;

Condreay, LD .

JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (10) :3338-3347

[3] Identification and characterization of mutations in hepatitis B virus resistant to lamivudine [J].

Allen, MI ;

Deslauriers, M ;

Andrews, CW ;

Tipples, GA ;

Walters, KA ;

Tyrrell, DLJ ;

Brown, N ;

Condreay, LD .

HEPATOLOGY, 1998, 27 (06) :1670-1677

[4] Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase [J].

Angus, P ;

Vaughan, R ;

Xiong, S ;

Yang, HL ;

Delaney, W ;

Gibbs, C ;

Brosgart, C ;

Colledge, D ;

Edwards, R ;

Ayres, A ;

Bartholomeusz, A ;

Locarnini, S .

GASTROENTEROLOGY, 2003, 125 (02) :292-297

[5]

Bartholomeusz A, 2004, ANTIVIR THER, V9, P149

[6] Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir [J].

Brunelle, MN ;

Jacquard, AC ;

Pichoud, C ;

Durantel, D ;

Carrouée-Durantel, S ;

Villeneuve, JP ;

Trépo, C ;

Zoulim, F .

HEPATOLOGY, 2005, 41 (06) :1391-1398

[7] A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients [J].

Chang, TT ;

Gish, RG ;

Hadziyannis, SJ ;

Cianciara, J ;

Rizzetto, M ;

Schiff, ER ;

Pastore, G ;

Bacon, BR ;

Poynard, T ;

Joshi, S ;

Klesczewski, KS ;

Thiry, A ;

Rose, RE ;

Colonno, RJ ;

Hindes, RG .

GASTROENTEROLOGY, 2005, 129 (04) :1198-1209

[8] Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro [J].

Chen, RYM ;

Edwards, R ;

Shaw, T ;

Colledge, D ;

Delaney, WE ;

Isom, H ;

Bowden, S ;

Desmond, P ;

Locarnini, SA .

HEPATOLOGY, 2003, 37 (01) :27-35

[9] In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-β-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil [J].

Chin, R ;

Shaw, T ;

Torresi, J ;

Sozzi, V ;

Trautwein, C ;

Bock, T ;

Manns, M ;

Isom, H ;

Furman, P ;

Locarnini, S .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (09) :2495-2501

[10] High barrier to resistance results in no emergence of entecavir resistance in nucleoside-Naive subjects during the first two years of therapy [J].

Colonno, R. J. ;

Rose, R. E. ;

Baldick, C. J. ;

Levine, S. M. ;

Klesczewski, K. ;

Tenney, D. J. .

JOURNAL OF HEPATOLOGY, 2006, 44 :S182-S182

← 1 2 3 4 5 6 7 8 9 →